MALDEN, Mass. (PRWEB) January 25, 2021 -- With years of feedback from Orthopedics, Neurosurgeons, and Interventional pain physicians, Sacrix has developed the third iteration of the SacroFuse threaded compression device for immediate stabilization of the sacroiliac joint for pain relief and ultimately fusion. This new design can be described as a screw and cage hybrid with 3 different thread combinations that is self-drilling, self-tapping and compresses across the Sacroiliac joint. Sacrix reported creating more space for graft containment equivalent to over 1cc. Sacrix can now claim to have the largest volume of space within its device for bone graft while maintaining superior biomechanical strength and increased pull-out strength over its previous design which was already leading the industry. The instrumentation is now simplified to allow for a 2-step technique with a 1.5cm incision, 100% percutaneous under fluoroscopy and bloodless. Sacrix reported performing over 20 labs in 2020, during the Covid-19 crisis, and 5 labs already in 2021.
Oscar Herrera, Senior Engineer and Product Manager of SacroFuse stated that: “This new hybrid implant is designed to ease insertion and maximize osteointegration. Improvements to instrumentation supporting the efficient technique and a “letter sized” footprint system case punctuate the release. These updates will enhance the user experience, while offering a safe, effective and simple solution to Sacroiliac Joint dysfunction.”
Dr. Kingsley R. Chin, and inventor and board-certified Orthopedic Spine Surgeon said “I think that having an Orthopedic spine surgeon develop this device and technique resulted in a strong device for reliable fixation but then having pain management and interventional physicians to give feedback pushed us to revolutionize the technique to make it the ultimate percutaneous less invasive technique with the aid of fluoroscopy”.
About Sacrix LLC
Sacrix is a KICVentures Group portfolio company focused on revolutionary percutaneous posterior sacroiliac fixation technologies for the treatment of sacroiliac dysfunction and sacroiliitis. Sacrix is patented and was FDA-cleared since 2015. Sacrix’s Gen1 screw was compared head-to-head with market leader SI bone (SIBN) and found to have a 400% increase in pull out strength.
About KICVentures Group
KICVentures Group is a global corporation who since 2005 has been leading waves of change with differentiated health technologies and is building a vertically and horizontally integrated healthcare portfolio. The company has headquarters in Boston, USA. http://www.kicventuresgroup.com
Sheng Deng, KICVentures Group, 9782323990, [email protected]
SOURCE KICVentures Group